Document is current
Any future updates will be listed below
-
Authors
Corvigno, Sara
Burks, Jared K.
Hu, Wei
Zhong, Yanping
Jennings, Nicholas B.
Fleming, Nicole D.
Westin, Shannon N.
Fellman, Bryan
Liu, Jinsong
Sood, Anil K. https://orcid.org/0000-0003-4242-1762
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30 CA016672)
the MD Anderson Ovarian Cancer SPORE (P50 CA217685,R35 CA209904, U01 CA213759)
American Cancer Society
Frank McGraw Memorial Chair in Cancer Research
- License Information
-
More Information
Article History
Received: 20 August 2021
Accepted: 22 August 2021
First Online: 2 September 2021
Declarations
:
: Sara Corvigno, Jared Burks, Yanping Zhong, Bryan Fellman, and Jinsong Liu have no conflicts of interest to declare. Wei Hu receives research support from Geistlich Pharma AG. Shannon Westin receives research support (to institution) from AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Cotinga Pharmaceuticals, Bayer, and ArQule. She receives consulting fees from AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Eisai, Pfizer, Merck, Circulogene, and Zentalis. Anil K. Sood is a shareholder of BioPath, and is a consultant for Merck, Astra Zeneca, and Kiyatec. Nicole Fleming is on the Advisory Boards of Tesaro and Pfizer/BMS.
: Waiver of informed consent was approved on the 27th of December 2017 and reviewed by Michelle D. Williams. The IRB responsible for review and approval of this waiver was The University of Texas IRB 5 IRB00006023.
